On Wednesday, I took part in a debate on widening the access to vital medicines. The Scottish Government has significantly improved access to new medicines in recent years, and furthermore, are currently in the process of implementing recommendations from a review which will mean faster access to new treatments.

Given ultra-orphan drugs are often very expensive, it is also vital that pharmaceutical companies play their part and bring a fair price, first time, to the process.